PTIE Pain Therapeutics Inc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pain Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Pain Therapeutics, Inc. (NASDAQGS: PTIE) concerning possible breaches of fiduciary duty. To obtain additional information, go to:

http://www.zlkdocs.com/PTIE-Info-Request-Form-6546

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
19/03/2018

Underlying

PTIEPain Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pain Therapeutics Inc

 PRESS RELEASE
Free
PTIE Pain Therapeuti...

Pain Therapeutics Announces Name Change to Cassava Sciences, Inc.

Pain Therapeutics Announces Name Change to Cassava Sciences, Inc. - Focus is on Neurodegenerative Diseases - AUSTIN, Texas, March 27, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a drug development company, announced a company name change to Cassava Sciences, Inc., effective immediately.  The new name was chosen to better reflect the Company’s strategic focus on drug development for neurodegenerative diseases, such as Alzheimer’s disease.  Beginning March 28, 2019, Cassava Sciences will trade on NASDAQ under the new ticker symbol: SAVA. “A new Company name is part...

March 27, 2019 1 EN
 PRESS RELEASE
Free
PTIE Pain Therapeuti...

Pain Therapeutics Reports 2018 Financial Results and Corporate Update

Pain Therapeutics Reports 2018 Financial Results and Corporate Update 2019 Focus Is on Alzheimer’s Disease, Rebranding the Company, Conducting Phase II Studies and Fiscal Discipline AUSTIN, Texas, March 25, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE) today reported financial results for the year ended December 31, 2018. Net loss in 2018 was $6.6 million, or $0.61 per share, compared to a net loss in 2017 of $11.9 million, or $1.82 per share. Cash used in operations during the year ended December 31, 2018 was $4.8 million. Cash and cash equivalents were $19.8 million ...

March 25, 2019 1 EN
 PRESS RELEASE
Free
PTIE Pain Therapeuti...

Pain Therapeutics Announces Feedback from Recent Meeting with FDA on ...

Pain Therapeutics Announces Feedback from Recent Meeting with FDA on REMOXY Going Forward, We Will Be Silent Regarding Future Expectations for REMOXY AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug development company, today announced feedback from a meeting held January 31, 2019 with the U.S. Food and Drug Administration (FDA) regarding the drug candidate, REMOXY ER.  REMOXY is the trade name for a new type of abuse-deterrent, extended-release gel formulation of oxycodone (CII) with physical/chemical properties intended to...

February 5, 2019 1 EN
 PRESS RELEASE
Free
PTIE Pain Therapeuti...

Pain Therapeutics Announces Academic Collaboration with The University...

Pain Therapeutics Announces Academic Collaboration with The University of Texas at Austin AUSTIN, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a drug development company, announced today it has entered into an academic collaboration with UT Austin in support of a product candidate aimed at pain management, abuse and addiction. The collaboration brings together the Company and UT Austin’s respective scientific expertise and capabilities, with a focus on validating a new technological innovation. The scope of work encompasses research and development to ...

January 17, 2019 1 EN
 PRESS RELEASE
Free
PTIE Pain Therapeuti...

Pain Therapeutics Awarded $1.5 Million Research Grant by National Inst...

Pain Therapeutics Awarded $1.5 Million Research Grant by National Institutes of Health Goal is To Develop a Blood-based Test for Alzheimer’s Disease AUSTIN, Texas, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug development company, announced today it has been awarded $1.5 million in research funding from the National Institutes of Health (NIH).  Today’s grant award is intended to support, over the next eighteen months, the Company’s on-going development of new technology to detect Alzheimer’s disease with a simple blood test. “Finding a ...

January 16, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch